Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL756368 | 0.83 | FOLH1 (0.47) | CTSKFOLH1CAPN1ITGA4 | |
| SCHEMBL18731295 | 0.83 | FOLH1 (0.47) | CTSKFOLH1CAPN1ITGA4 | |
| SCHEMBL7300949 | 0.80 | ITGB3 (0.41) | MAPK1L3MBTL1ITGB3ITGA2BSMN1; SMN2 | |
| SCHEMBL7300962 | 0.80 | ITGB3 (0.41) | MAPK1L3MBTL1ITGB3ITGA2BSMN1; SMN2 | |
| SCHEMBL478732 | 0.79 | SCN9A (0.53) | CTSKFOLH1ITGB3ITGA2BCAPN1 | |
| SCHEMBL5717580 | 0.79 | SCN9A (0.53) | CTSKFOLH1ITGB3ITGA2BCAPN1 | |
| SCHEMBL478735 | 0.79 | SCN9A (0.53) | CTSKFOLH1ITGB3ITGA2BCAPN1 | |
| SCHEMBL20272602 | 0.79 | CPB2 (0.47) | CTSKFOLH1CAPN1 | |
| SCHEMBL7473483 | 0.79 | ITGB3 (0.52) | CTSKITGB3ITGA2B | |
| SCHEMBL5086307 | 0.79 | HDAC6 (0.49) | CTSKITGB3ITGA2BACEACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234982-A1 | SUBSTITUTED HYDANTOINS AS MEK KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080523-A1 | SUBSTITUTED HYDANTOINS AS MEK KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| EP-1989186-A1 | HYDANTOIN BASED KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008101840-A1 | COMBINATION OF ERLOTINIB AND MEK-INHIBITORS FOR INHIBITING PROLIFERATION OF TUMOR CELLS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| WO-2007096259-A1 | HYDANTOIN BASED KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-30 | — | — | WO | disclosed |
| EP-1791837-A1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | F. Hoffmann-Roche AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006029862-A1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | disclosed |
| CN-1492874-A | Macrolide antibiotics | — | 2004-04-28 | — | — | CN | disclosed |